Some features of the kinetics and equilibrium of drug binding to plasma proteins

Bibliography

• Wilkinson GR. Plasma and tissue binding considerations in drug disposition. Drug Metab Dispos 1983;14:427-65
   Web of Science ®Google Scholar
• Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharm Ther 2002;71:115-21
   PubMed Web of Science ®Google Scholar
• Kwon Y. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. New York: Kluwer Academic/Plenum Publishers,2001
   Google Scholar
• Borga O, Borga B. Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm 1997;25:63-77
   PubMedGoogle Scholar
• Berezhkovskiy LM. On the calculation of the concentration dependence of drug binding to plasma proteins with multiple binding sites of different affinities: determination of the possible variation of the unbound drug fraction and calculation of the number of binding sites of the protein. J Pharm Sci 2007;96:249-57
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi-N N, Porquet D. Alfa-1-acid glycoprotein. Biochim Biophys Acta 2000;1482(1-2):157-71
   PubMed Web of Science ®Google Scholar
• Shami MR, Skellern GG, Whiting B. Binding of [3H]mianserin to bovine serum albumin, human serum albumin and α1-acid glycoprotein. J Pharm Pharmacol 1984;36:16-20
   PubMed Web of Science ®Google Scholar
• Aki H, Yamamoto M. Thermodynamics of the binding of phenothiazines to human plasma, human serum albumin and α1-acid glycoprotein: a calorimetric study. J Pharm Pharmacol 1989;41:674-9
   PubMed Web of Science ®Google Scholar
• Cooper A, Johnson CM. Introduction to Microcalorimetry and Biomolecular Energetics. Microscopy, Optical Spectroscopy, and Macroscopic Techniques. Series: Methods Mol Biol 1993;22:109-24
   Google Scholar
• Meyer MC, Gutman DE. Dynamic dialysis as a method for studying protein binding II: Evaluation of the method with a number of binding systems. J Pharm Sci 1970;59:39-48
   PubMed Web of Science ®Google Scholar
• Robertson JS, Madsen BW. Kinetic approach to drug-protein binding. J Pharm Sci 1974;63:234-9
   PubMed Web of Science ®Google Scholar
• Yuan J, Yang DC, Birkmeier J, Stolzenbach J. Determination of protein binding by in vitro charcoal adsorption. J Pharmacokinet Biopharm 1995;23:41-55
   PubMedGoogle Scholar
• Schuhmacher J, Kohlsdorfer C, Bühner K, et al. High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 2004;93:816-30
   PubMed Web of Science ®Google Scholar
• Musteata FM, Pawliszyn J, Qian MG, et al. 2006. Determination of drug plasma protein binding by solid phase microextraction J Pharm Sci 2006;95:1712-22
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal. J Pharmacokinet Pharmacodyn 2006;35:595-608
   Google Scholar
• Oravcová J, Böhs B, Lindner W. 1996. Drug-protein binding studies new trends in analytical and experimental methodology. J Chromatogr B 1996;677: 1-28
   PubMed Web of Science ®Google Scholar
• Rich RL, Day YS, Morton TA, Myszka DG. High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE. Anal Biochem 2001;296:197-207
   PubMed Web of Science ®Google Scholar
• Day YS, Myszka DG. Characterizing a drug's primary binding site on albumin. J Pharm Sci 2003;92:333-43
   PubMed Web of Science ®Google Scholar
• Parikh HH, McElwain K, Balasubramanian V, et al. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. Pharm Res 2000;17:632-7
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM, Khojasteh SC, Halladay JS, Hop CE. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. J Pharm Sci 2008; Available from: on-line in the Early View of the Journal
   PubMedGoogle Scholar
• Maruyama T, Otagary M, Takadate A. Characterization of drug binding sites on α1-acid glycoprotein. Chem Pharm Bull (Tokyo) 1990;38:1688-91
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Sukimoto K, Nishi K, et al. Characterization of ligand binding sites on the α1-acid glycoprotein in humans, bovines and dogs. Drug Metab Pharmacokinet 2002;17:300-6
   PubMedGoogle Scholar
• Berezhkovskiy LM, Astafieva IV, Cardoso C. 2002. Analysis of peptide affinity to major histocompatibility complex protein for the two-step binding mechanism. Anal Biochem 202;308:239-46
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Consideration of the linear concentration increase of the unbound drug fraction in plasma. J Pharm Sci 2008. [Epub 14 August 2008]
   PubMedGoogle Scholar
• Rolan PE. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-8
   PubMed Web of Science ®Google Scholar
• Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data J Pharm Sci 2006;95:2778-87
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Backman JT, Neuvonen PJ. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:433-9
   PubMed Web of Science ®Google Scholar
• Levine I. Physical Chemistry. New-York: McGrow-Hill. 1978
   Google Scholar
• Berezhkovskiy LM. On the temperature dependence of the unbound drug fraction in plasma: ultrafiltration method may considerably underestimate the true value for highly bound drugs. Drug Discov Ther 2008;2:74-6
   PubMedGoogle Scholar
• Aki H, Yamamoto M. Thermodynamic characterization of drug binding to human serum albumin by isothermal titration microcalorimetry. J Pharm Sci 1994;83:1712-6
   PubMed Web of Science ®Google Scholar
• Chen W, Chang C-E, Gilson MK. Calculation of cyclodextrin binding affinities: energy, entropy and implications for drug design. Biophys J 2004;87:3035-49
   PubMed Web of Science ®Google Scholar
• Freedman FB, Johnson JA. Equilibrium and kinetic properties of the Evans blue-albumin system. Am J Physiol 1969;216:675-81
   PubMed Web of Science ®Google Scholar
• Smoluchowski MV. Attempt of a mathematical theory for the kinetics of coagulation of colloid solutions. Z Phys Chem 1917;92:129-68
   Google Scholar
• Berezhkovskiy LM. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 2004;93:364-74
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 2004;93:1628-40
   PubMed Web of Science ®Google Scholar
• Oppenheimer JH, Schwartz JL, Surks MI. Determination of common parameters of iodothyronine metabolism and distribution in man by noncompartmental analysis. J Clin Endocrinol Metab 1975;41:319-24
   PubMed Web of Science ®Google Scholar
• Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979;68:1071-4
   PubMed Web of Science ®Google Scholar
• Gillette JR. Factors affecting drug metabolism. Ann NY Acad Sci 1971;179:43-66
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Heydari A, et al. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 2007;35:501-2
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977;5:625-53
   PubMedGoogle Scholar
• Berezhkovskiy LM. The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: the traditional equation may considerably overestimate the true value. J Pharm Sci 2006;95:834-48
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters. J Pharm Sci 2008; Available from: on-line in the Early View of the Journal
   PubMedGoogle Scholar
• Berezhkovskiy LM. The analysis of peptide affinity and its binding kinetics to DR1DW1 major histocompatibility complex protein. J Biophys Chem 1999;77:183-94
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. On the kinetics of peptide binding to MHC proteins. J Biophys Chem 1998;71:1-8
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the “first pass” after oral administration. J Pharm Sci 2006;95:828-33
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma. J Pharm Sci 2007;96:3432-43
   PubMed Web of Science ®Google Scholar